Ioana C. Hone

Contatto Relazioni con gli Investitori presso LINEAGE CELL THERAPEUTICS, INC.

Health Technology

Profilo

Ioana C.
Hone is currently working as an Investor Relations Contact at Lineage Cell Therapeutics, Inc. Previously, she worked as a Director-Investor Relations at LifeVantage Corp., Mast Therapeutics, Inc., and as an Investor Relations Contact at Savara, Inc.

Posizioni attive di Ioana C. Hone

Società	Posizione	Inizio
LINEAGE CELL THERAPEUTICS, INC.	Contatto Relazioni con gli Investitori	-

Tutte le posizioni attive di Ioana C. Hone

Precedenti posizioni note di Ioana C. Hone

Società	Posizione	Fine
LIFEVANTAGE CORPORATION	Public Communications Contact	-
SAVARA INC.	Contatto Relazioni con gli Investitori	-
Mast Therapeutics, Inc. Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA.	Contatto Relazioni con gli Investitori	-

Vedi nel dettaglio l'esperienza di Ioana C. Hone

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Ioana C. Hone

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	3
LIFEVANTAGE CORPORATION	Health Technology
SAVARA INC.	Health Technology
LINEAGE CELL THERAPEUTICS, INC.	Health Technology

Aziende private	1
Mast Therapeutics, Inc. Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA.	Health Technology